SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Passive Stake in Brainstorm Cell Therapeutics

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.99% in Brainstorm Cell Therapeutics Inc. as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed an Amendment No. 1 to Schedule 13G.
• The filing discloses their beneficial ownership in Brainstorm Cell Therapeutics Inc. (Issuer) Common Stock, $0.00005 par value.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 299,548 shares of the Issuer's common stock.
• This ownership represents 4.99% of the Issuer's outstanding common stock.
• Armistice Capital, LLC, a Delaware entity, is the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd, a United States citizen, is the managing member of Armistice Capital, LLC.
• The shares are held with shared voting power and shared dispositive power for both Armistice Capital, LLC and Steven Boyd.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the Issuer.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a factual, routine regulatory filing disclosing a passive ownership stake. It does not contain positive or negative performance indicators, strategic announcements, or forward-looking statements that would influence sentiment.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of a passive investment stake by an investment manager and its principal in a biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact of the investment itself.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive investor's stake in the company.
• Management: Awareness of a notable institutional investor's position.

Next Steps

• The Reporting Persons will be required to file further amendments to this Schedule 13G if their beneficial ownership percentage changes significantly (e.g., crosses a 1% threshold up or down) or if their investment intent changes from passive to active.

Key Dates

Keywords

Brainstorm Cell Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Passive Investment